| Identification | Back Directory | [Name]
BMS-986020 | [CAS]
1257213-50-5 | [Synonyms]
AM152
CS-2492
BMS-986020
BMS-986020;BMS 986020;BMS986020
1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid
(R)-1-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]- | [Molecular Formula]
C29H26N2O5 | [MDL Number]
MFCD30489743 | [MOL File]
1257213-50-5.mol | [Molecular Weight]
482.53 |
| Chemical Properties | Back Directory | [Melting point ]
174-180°C | [Boiling point ]
664.8±55.0 °C(Predicted) | [density ]
1.309±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
4.19±0.20(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
BMS 986020 is a potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells.1 Formulations containing BMS 986020 are being investigated in clinical trials for efficacy in idiopathic pulmonary fibrosis.2 | [Uses]
BMS-?986020 is an LPA-1 antagonist which may be used in the inhibition and treatment of bleomycin-induced pulminary fibrosis. |
|
|